Literature DB >> 6499952

Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerol.

B K Colasanti, C R Craig, R D Allara.   

Abstract

Cannabinol or cannabigerol was administered to cats topically in doses of 250, 500 and 1000 micrograms as a single drop or chronically via osmotic minipumps (20 micrograms hr-1) over a period of 9 days. While cannabinol had a modest effect on intraocular pressure after a single dose, it caused a more significant reduction in ocular tension during chronic administration. Cannabigerol had similar effects, but the magnitude of response to its chronic administration was greater. Cannabinol but not cannabigerol caused conjunctival erythema and hyperemia. After systemic administration of cannabinol (20, 40 or 80 mg kg-1) to rats, 8-13 Hz polyspike discharges appeared in the electrocorticogram during wakefulness and during rapid eye movement sleep episodes. Cannabigerol (10, 30 and 100 mg kg-1) lacked this effect. These results indicate that chronic administration of these cannabinoids lowers ocular tension considerably. Like marihuana and delta-9-tetrahydrocannabinol, cannabinol produced both ocular toxicity and neurotoxicity. As cannabigerol lacked these toxicities, it appears that the ocular hypotensive effect of this cannabinoid is somewhat dissociable from both the adverse central and ocular effects accompanying marihuana intake.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6499952     DOI: 10.1016/0014-4835(84)90013-7

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  10 in total

Review 1.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

2.  Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour.

Authors:  Serena Deiana; Akihito Watanabe; Yuki Yamasaki; Naoki Amada; Marlene Arthur; Shona Fleming; Hilary Woodcock; Patricia Dorward; Barbara Pigliacampo; Steve Close; Bettina Platt; Gernot Riedel
Journal:  Psychopharmacology (Berl)       Date:  2011-07-28       Impact factor: 4.530

3.  Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews.

Authors:  Erin M Rock; Jennifer M Goodwin; Cheryl L Limebeer; Aviva Breuer; Roger G Pertwee; Raphael Mechoulam; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2011-01-18       Impact factor: 4.530

4.  Topical WIN55212-2 alleviates intraocular hypertension in rats through a CB1 receptor mediated mechanism of action.

Authors:  Matt H Oltmanns; Sandeep S Samudre; Ivan G Castillo; Alireza Hosseini; Aron H Lichtman; Robert C Allen; Frank A Lattanzio; Patricia B Williams
Journal:  J Ocul Pharmacol Ther       Date:  2008-02       Impact factor: 2.671

Review 5.  Cannabinoids and glaucoma.

Authors:  I Tomida; R G Pertwee; A Azuara-Blanco
Journal:  Br J Ophthalmol       Date:  2004-05       Impact factor: 4.638

6.  The impacts of individual and combined exposure to cadmium and lead on intraocular pressure, electroretinography, and residual changes in the rabbit eyes.

Authors:  Yasmina M Abd-Elhakim; Khlood M El Bohi; Nabela I El Sharkawy; Manar A Ghali; Sarah Haseeb
Journal:  Environ Sci Pollut Res Int       Date:  2019-09-13       Impact factor: 4.223

Review 7.  Effects of Cannabinoid Agonists and Antagonists on Sleep in Laboratory Animals.

Authors:  Maureen L Petrunich-Rutherford; Michael W Calik
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  The effects of subacute exposure to a water-soluble cannabinol compound in male mice.

Authors:  Melissa M Bailey; Mariah C Emily Mills; Ashley E Haas; Kelly Bailey; Robert C Kaufmann
Journal:  J Cannabis Res       Date:  2022-07-27

Review 9.  Cannabinoids in health and disease.

Authors:  Natalya M Kogan; Raphael Mechoulam
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

10.  SuperPain--a resource on pain-relieving compounds targeting ion channels.

Authors:  Björn O Gohlke; Robert Preissner; Saskia Preissner
Journal:  Nucleic Acids Res       Date:  2013-11-22       Impact factor: 16.971

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.